Reduction in Sino-Nasal Outcome Test-22 (SNOT-22) Scores*
*Multiplicity adjustments were not applied for secondary endpoints and results could represent chance findings; therefore, these data and comparisons between studies require cautious interpretation.
The comparator used in the pivotal clinical studies was a liquid placebo delivered with an Optinose Exhalation Delivery System (EDS).1
Results shown above are from NAVIGATE II and are consistent with results observed in patients participating in NAVIGATE I.1
- Data on file. OptiNose US, Inc.
- Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2018; In press.
- Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-454.
- Le PT, Soler ZM, Jones R, et al. Systematic review and meta-analysis of SNOT-22 outcomes after surgery for chronic rhinosinusitis with nasal polyposis. Otolaryngol Head Neck Surg. 2018; In press.